Request Demo

Last update 08 May 2025

Evangelisches Krankenhaus Göttingen-Weende EV

Private Company|Germany

Last update 08 May 2025

Overview

Pipeline

Deal

Translational Medicine

Overview

100 Clinical Results associated with Evangelisches Krankenhaus Göttingen-Weende EV

0 Patents (Medical) associated with Evangelisches Krankenhaus Göttingen-Weende EV

Literatures (Medical) associated with Evangelisches Krankenhaus Göttingen-Weende EV

01 May 2025·Strahlentherapie und Onkologie

Neoadjuvant radiochemotherapy in patients with high-risk locally advanced cervical cancer—results of a clinical series

Article

Author: Guhlich, M ; Dröge, L H ; Seif, A ; Fischer, L A ; Zwerenz, C M ; Bendrich, S ; Leu, M ; Donath, S ; Ammon, H E ; El Shafie, R ; Bremmer, F ; Ziegler, S ; Pagel, C F ; Rieken, S ; Fleckenstein, G ; Ziegler, D A ; Schirmer, M A ; Oelmann, J T ; Hess, C F ; Hille, A

PURPOSENeoadjuvant radiochemotherapy (NARCT) is an established standard of care in various tumor entities, promoting high response rates at commonly lower toxicities as compared to adjuvant approaches. This retrospective analysis was designed to investigate NARCT in early-stage high-risk cervical cancer.METHODSForty patients with early-stage high-risk cervical cancer (i.e., L1, V1, G3, N+, > ²/₃ stromal invasion, > 4 cm tumor size, borderline resectability) were treated with NARCT prior to surgical resection. Downstagings based on clinical, imaging, and pathological responses were recorded. Survival rates were calculated according to Kaplan-Meier, and prognostic factors were analyzed with uni- and multivariable Cox regression analyses using SPSS software (v. 26; IBM Corp., Armonk, NY, USA).RESULTSBoth NARCT and subsequent tumor resection were feasible and conducted in 39 of 40 patients (95%). Early toxicity was moderate, with no grade 3 or higher toxicities following NARCT and surgery. NARCT yielded significant downstaging in all patients, and pathological complete remission (pCR) was achieved in 14 patients (36%). After 5 years, overall survival (OS), freedom from local progression (FFLP), and freedom from distant progression (FFDP) rates were 84.2%, 75.9%, and 73.1%, respectively. Late proctitis (grade 1 in 8%) and urinary cystitis (grade 1-3 in 35%) occurred at acceptable rates.CONCLUSIONIn resectable early-stage high-risk cervical cancer, NARCT is feasible and safe. Clinical, imaging, and pathological response rates are high. Impressive long-term survival and tumor control rates at modest toxicities encourage the initiation of a prospective and randomized trial.

01 Jul 2024·Pneumologie

herausgegeben von der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin

Review

Author: Hämäläinen, Nina ; Heppner, Hans ; Neumann, Peter ; Dreher, Michael ; Fuchs, Hans ; Bickenbach, Johannes ; Braune, Stephan ; Geiseler, Jens ; Walterspacher, Stephan ; Westhoff, Michael ; Kluge, Stefan ; Schimandl, Dorit ; Dubb, Rolf ; Schönhofer, Bernd ; Lepper, Philipp M. ; Meyer, F. Joachim ; Arzt, Michael ; Windisch, Wolfram ; Kochanek, Matthias ; Delis, Sandra ; Bachmann, Martin ; Neumann, Bernhard ; Putensen, Christian ; Schreiter, Dierk ; Dellweg, Dominic

01 Jul 2024·Pneumologie

herausgegeben von der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin

Article

Author: Hämäläinen, Nina ; Heppner, Hans ; Neumann, Peter ; Dreher, Michael ; Bickenbach, Johannes ; Fuchs, Hans ; Braune, Stephan ; Geiseler, Jens ; Westhoff, Michael ; Walterspacher, Stephan ; Kluge, Stefan ; Schimandl, Dorit ; Dubb, Rolf ; Schönhofer, Bernd ; Lepper, Philipp M. ; Meyer, F. Joachim ; Arzt, Michael ; Windisch, Wolfram ; Kochanek, Matthias ; Delis, Sandra ; Bachmann, Martin ; Neumann, Bernhard ; Putensen, Christian ; Schreiter, Dierk ; Dellweg, Dominic

100 Deals associated with Evangelisches Krankenhaus Göttingen-Weende EV

100 Translational Medicine associated with Evangelisches Krankenhaus Göttingen-Weende EV

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 15 Nov 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Evangelisches Krankenhaus Göttingen-Weende EV

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 15 Nov 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing